edotreotide has been researched along with Carcinoma, Medullary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; Grana, C; Handkiewicz-Junak, D; Lopera Sierra, M; Mäcke, HR; Mazzetta, C; Paganelli, G; Rocca, P | 1 |
| Cybulla, M; Otte, A; Weiner, SM | 1 |
2 other study(ies) available for edotreotide and Carcinoma, Medullary
| Article | Year |
|---|---|
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Topics: Adult; Aged; Carcinoma, Medullary; Female; Humans; Male; Middle Aged; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Retrospective Studies; Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2004 |
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Medullary; Humans; Hypertension, Renal; Kidney Failure, Chronic; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2002 |